Rhythm Pharmaceuticals, Inc. (RYTM)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$89.27-1.79%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Rhythm Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	102.06M
EPS	—	-0.702
Annual ending 2026-12-31
Revenue	—	318.26M
EPS	—	-2.946
Annual ending 2027-12-31
Revenue	—	561.86M
EPS	—	-0.646

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
IMCIVREE global sales revenue	A primary condition in Rhythm Pharmaceuticals, Inc.'s published investment case. The stated target is >= $194 million.	Improving	IMCIVREE revenue falls below $130 million in 2025	Revenue: $71.255M FY2026-Q2; GAAP. Published target: >= $194 million. The stored target says 2025-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 4, 202671,255,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5100f37e-adc5-4f04-ad2f-54c990d498b8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Expanded market authorization for IMCIVREE	The company expanded market authorization for IMCIVREE to treat more obesity types.	Improving	Failure to maintain or expand IMCIVREE market authorization by end 2026	Japan launch completed vs 2026 target News confirms IMCIVREE launch in Japan for obesity, expanding market authorization strongly. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Non-GAAP operating expenses	Operating expenses are guided to stay between $385M and $415M in 2026.	Intact	Operating expenses exceed $415 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.65

$-0.79 → $-0.65 · observed estimates

FY2027 revenue$0.56B

$0.54B → $0.56B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.79	$539,158,000	10 / 16
2026-07-25	$-0.74	$538,995,330	9 / 15
2026-07-26	$-0.74	$538,995,330	9 / 15
2026-07-27	$-0.74	$538,995,330	9 / 15
2026-07-28	$-0.74	$538,995,330	9 / 15
2026-07-29	$-0.65	$545,758,110	10 / 16
2026-07-30	$-0.68	$545,751,463	8 / 11
2026-07-31	$-0.65	$545,758,110	10 / 16
2026-08-01	$-0.68	$545,751,463	9 / 12
2026-08-02	$-0.65	$545,758,110	10 / 16
2026-08-03	$-0.68	$545,751,463	9 / 12
2026-08-04	$-0.65	$545,758,110	10 / 16
2026-08-05	$-0.47	$552,254,150	9 / 16
2026-08-06	$-0.68	$545,751,463	9 / 12
2026-08-08	$-0.67	$561,172,362	7 / 12
2026-08-09	$-0.64	$559,546,780	9 / 16
2026-08-10	$-0.64	$559,546,780	9 / 16
2026-08-12	$-0.61	$561,109,280	11 / 16
2026-08-13	$-0.67	$561,172,362	7 / 12
2026-08-14	$-0.67	$561,172,362	7 / 12
2026-08-15	$-0.67	$561,172,362	8 / 12
2026-08-16	$-0.67	$561,172,362	8 / 12
2026-08-17	$-0.67	$561,172,362	8 / 12
2026-08-18	$-0.67	$561,172,362	8 / 12
2026-08-19	$-0.67	$561,172,362	8 / 12
2026-08-20	$-0.67	$561,110,146	10 / 12
2026-08-21	$-0.67	$561,110,146	10 / 12
2026-08-22	$-0.67	$561,110,146	10 / 12
2026-08-23	$-0.67	$561,110,146	10 / 12
2026-08-24	$-0.67	$561,110,146	10 / 12
2026-08-25	$-0.67	$561,110,146	10 / 12
2026-08-26	$-0.67	$561,110,146	10 / 12
2026-08-27	$-0.67	$561,110,146	10 / 12
2026-08-28	$-0.67	$561,110,146	10 / 12
2026-08-29	$-0.67	$560,231,184	10 / 12
2026-08-30	$-0.67	$560,231,184	10 / 12
2026-08-31	$-0.67	$560,231,184	10 / 13
2026-09-01	$-0.67	$560,231,184	10 / 13
2026-09-02	$-0.67	$560,231,184	11 / 13
2026-09-03	$-0.67	$560,231,184	10 / 13
2026-09-04	$-0.67	$560,231,184	10 / 13
2026-09-05	$-0.67	$560,231,184	10 / 13
2026-09-06	$-0.67	$560,231,184	10 / 13
2026-09-07	$-0.67	$560,231,184	10 / 13
2026-09-08	$-0.67	$560,231,184	10 / 13
2026-09-09	$-0.67	$560,231,184	10 / 13
2026-09-10	$-0.67	$560,231,184	10 / 13
2026-09-11	$-0.67	$560,231,184	10 / 13
2026-09-12	$-0.67	$560,231,184	10 / 13
2026-09-13	$-0.67	$560,231,184	10 / 13
2026-09-14	$-0.67	$560,231,184	10 / 13
2026-09-15	$-0.66	$554,537,066	10 / 13
2026-09-16	$-0.66	$554,537,066	10 / 13
2026-09-17	$-0.66	$554,537,066	10 / 13
2026-09-18	$-0.66	$554,537,066	10 / 13
2026-09-19	$-0.66	$554,537,066	10 / 13
2026-09-20	$-0.64	$554,537,066	10 / 13
2026-09-21	$-0.64	$554,537,066	10 / 13
2026-09-22	$-0.70	$550,407,945	10 / 13
2026-09-23	$-0.70	$550,407,945	10 / 13
2026-09-24	$-0.70	$550,407,945	10 / 13
2026-09-25	$-0.70	$550,407,945	10 / 13
2026-09-26	$-0.70	$550,407,945	10 / 13
2026-09-27	$-0.70	$550,407,945	10 / 13
2026-09-28	$-0.70	$550,407,945	10 / 13
2026-09-29	$-0.70	$550,407,945	10 / 13
2026-09-30	$-0.70	$550,407,945	10 / 13
2026-10-01	$-0.70	$550,407,945	10 / 13
2026-10-02	$-0.70	$550,407,945	10 / 13
2026-10-03	$-0.70	$550,407,945	10 / 13
2026-10-04	$-0.70	$550,407,945	10 / 13
2026-10-05	$-0.70	$550,407,945	10 / 13
2026-10-06	$-0.70	$550,407,945	10 / 13
2026-10-07	$-0.70	$550,407,945	10 / 13
2026-10-08	$-0.70	$550,407,945	10 / 13
2026-10-09	$-0.65	$558,132,945	10 / 13
2026-10-10	$-0.65	$558,132,945	10 / 13
2026-10-11	$-0.65	$558,118,117	10 / 13
2026-10-12	$-0.65	$558,118,117	10 / 13
2026-10-13	$-0.64	$559,428,816	10 / 13
2026-10-14	$-0.64	$559,428,816	11 / 13
2026-10-15	$-0.64	$559,428,816	11 / 14
2026-10-16	$-0.65	$558,782,302	11 / 14
2026-10-17	$-0.65	$558,782,302	11 / 14
2026-10-18	$-0.65	$561,856,218	11 / 15
2026-10-19	$-0.65	$561,856,218	11 / 15
2026-10-20	$-0.65	$561,856,218	11 / 15
2026-10-21	$-0.65	$561,856,218	11 / 15
2026-10-22	$-0.65	$561,856,218	12 / 15
2026-10-23	$-0.65	$561,856,218	12 / 15
2026-10-24	$-0.65	$561,856,218	12 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	15	1
2026-06-01	15	1
2026-07-01	16	1
2026-08-01	15	2
2026-09-01	16	2
2026-10-01	17	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 17 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightOct 12

$130.00New observation · no comparable prior

RBC CapitalOct 8 · prior Jul 7

$141.00 → $159.00+12.8%

$0$87.45$174.90

1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

IMCIVREE global sales revenueRevenue: $71.255M
Non-GAAP operating expensesDirect metric needs a verified mapping

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-35.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Rhythm Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making growth business, not an established compounder. The multi-year view is in watch status: commercial and regulatory progress is visible, but recent financial performance remains below its industry cohort.

What's priced into Rhythm Pharmaceuticals, Inc.

The valuation is expensive versus peers, with a durable premium reflected in the evidence, while the model’s confidence is low. The expectations gap is negative, suggesting the premium may leave limited room for execution to fall short, though no valuation fragility gates have fired.

What the fundamentals likely do

Near term, IMCIVREE growth and new market access support revenue expansion: global product revenue rose 19% from the first to the second quarter of 2026, and management anticipates a Japan launch by year-end. Pipeline progress is mixed, and rising research and selling expenses keep the business loss-making; the narrower 2026 expense range shows active cost management. A guidance cut or weakening employment data could add pressure, while the near-term miss-risk signal is quiet despite elevated industry risk.

What Rhythm Pharmaceuticals, Inc. hinges on

Over the next one to three years, the thesis hinges on whether IMCIVREE’s U.S. growth and new authorizations translate into sustained commercial expansion. Clinical progress in MC4R agonists, expense discipline, and management’s ability to avoid guidance cuts are key company-specific swing factors. Healthcare-sector momentum may help the backdrop if major peers continue to report strong results, while weaker employment data could intensify concerns across the sector.